Previous 10 | Next 10 |
2023-03-16 09:09:42 ET Galectin Therapeutics ( NASDAQ: GALT ) said a data and safety monitoring board (DSMB) gave greenlight to continue a phase 2b/3 trial of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The DSMB dec...
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its third data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive...
NORCROSS, Ga., March 02, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study...
NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Ass...
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in...
Summary The company is all-in on the results of one clinical trial coming in 2024. They have to borrow, albeit at favorable terms, to stay afloat until then. There are few, if any, catalysts in the meantime. Galectin Therapeutics ( GALT ), is a microcap (<$70 millio...
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of ...
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6 th Obesity and NASH Drug Development Summit in Boston, MA. On No...
Galectin Therapeutics press release ( NASDAQ: GALT ): Q3 GAAP EPS of -$0.14. The company believes it has sufficient cash of $15.8M, including availability under its $60 million line of credit, to fund currently planned operations and research and development activities thr...
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2022. These results ...
News, Short Squeeze, Breakout and More Instantly...
Galectin Therapeutics Inc. Company Name:
GALT Stock Symbol:
NASDAQ Market:
Galectin Therapeutics Inc. Website:
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024...
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-lin...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detai...